Alnylam Pharmaceuticals (ALNY) Operating Expenses (2009 - 2026)

Alnylam Pharmaceuticals' Operating Expenses history runs 18 years deep, the most recent figure standing at $898.5 million for Q1 2026.

• Quarterly Operating Expenses rose 55.97% year-over-year to $898.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 billion (up 43.49% YoY) and the FY2025 annual result came in at $3.2 billion, up 32.46% from the prior year.
• Operating Expenses was $898.5 million for Q1 2026 at Alnylam Pharmaceuticals, down from $965.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $965.3 million in Q4 2025 and bottomed at $360.0 million in Q1 2022.
• A 5-year average of $615.8 million and a median of $556.1 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses retreated 1.05% — and 2026, when it surged 55.97%.
• Alnylam Pharmaceuticals' Operating Expenses stood at $523.6 million in 2022, then rose by 6.2% to $556.1 million in 2023, then advanced by 25.57% to $698.3 million in 2024, then soared by 38.23% to $965.3 million in 2025, then dropped by 6.92% to $898.5 million in 2026.
• Business Quant data shows ALNY's Operating Expenses at $898.5 million in Q1 2026, $965.3 million in Q4 2025, and $881.0 million in Q3 2025.